Kennesaw State University researchers are piloting Sandrapp, an AI app that matches lonely older adults with compatible people for real relationships rather than conversation with a chatbot — a deliberate counterpoint to robot companions like ElliQ, which a Houston psychologist warns can deepen isolation instead of easing it.
GoGuardian's Beacon software now scans what students type into ChatGPT, Gemini, and other AI chatbots for signs of self-harm, and the company says it's flagged thousands of at-risk students — but reporting shows the system both over-alerts and misses real warnings, and GoGuardian won't release failure-rate data.
EarSmartAI raised a $250,000 pre-seed round to build an AI-powered smart otoscope that lets parents screen kids for ear infections at home, joining academic efforts at Pittsburgh and Washington that have already shown similar tools can outperform routine clinical exams.
A 2026 meta-analysis of 42 studies and nearly 35,000 patients confirms AI-assisted colonoscopy finds more adenomas and misses fewer polyps, but wide prediction intervals and signs of publication bias mean the benefit isn't consistent everywhere — and exams take slightly longer.
A July 2026 field report from Ethiopia's Eliminate TB Project shows AI chest X-ray screening, now live in 225 health facilities, found 84% of all nationally detected TB cases despite covering just 68% of people screened — with hit rates varying sharply by population group.
At AACR 2026, Natera, MD Anderson, and a multi-institution NCI-led team showed AI models that predict cancer mutations and immunotherapy response directly from routine pathology slides, with Natera reporting 98% accuracy on a key colorectal biomarker — though none of it is peer-reviewed yet.
A federated-learning AI called OsteoPredict, presented at the World Congress on Osteoporosis 2026, found it can flag likely osteoporosis from routine chest X-rays with 91% sensitivity, potentially catching at-risk patients who never get a dedicated bone scan.
Harrison.ai won FDA clearance for an AI that triages stroke on the very first brain scan patients receive, rather than the follow-up angiogram most stroke-AI tools rely on, with sensitivity above 85% in its submission data.
Insilico Medicine has dosed the first patients in a 320-person Phase III trial of rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis, after earlier-stage results showed a lung-function improvement that reversed the typical decline seen on placebo.
UpDoc has won FDA clearance for a patient-facing large language model that gives adults with type 2 diabetes voice- and text-based insulin titration guidance with no mandatory physician review step, a first that is already drawing as much scrutiny over governance as praise for the technology.